BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Behr M, Kaufmann JK, Ketzer P, Engelhardt S, Mück-Häusl M, Okun PM, Petersen G, Neipel F, Hassel JC, Ehrhardt A, Enk AH, Nettelbeck DM. Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds. PLoS One 2014;9:e95723. [PMID: 24760010 DOI: 10.1371/journal.pone.0095723] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Weklak D, Pembaur D, Koukou G, Jönsson F, Hagedorn C, Kreppel F. Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions. Viruses 2021;13:1300. [PMID: 34372506 DOI: 10.3390/v13071300] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Moaven O, Mangieri CW, Stauffer JA, Anastasiadis PZ, Borad MJ. Strategies to Develop Potent Oncolytic Viruses and Enhance Their Therapeutic Efficacy. JCO Precis Oncol 2021;5:PO. [PMID: 34250395 DOI: 10.1200/PO.21.00003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Ungerechts G, Engeland CE, Buchholz CJ, Eberle J, Fechner H, Geletneky K, Holm PS, Kreppel F, Kühnel F, Lang KS, Leber MF, Marchini A, Moehler M, Mühlebach MD, Rommelaere J, Springfeld C, Lauer UM, Nettelbeck DM. Virotherapy Research in Germany: From Engineering to Translation. Hum Gene Ther 2017;28:800-19. [PMID: 28870120 DOI: 10.1089/hum.2017.138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
4 Cheng T, Song Y, Zhang Y, Zhang C, Yin J, Chi Y, Zhou D. A novel oncolytic adenovirus based on simian adenovirus serotype 24. Oncotarget 2017;8:26871-85. [PMID: 28460470 DOI: 10.18632/oncotarget.15845] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
5 Guo J, Mondal M, Zhou D. Development of novel vaccine vectors: Chimpanzee adenoviral vectors. Hum Vaccin Immunother 2018;14:1679-85. [PMID: 29300685 DOI: 10.1080/21645515.2017.1419108] [Cited by in Crossref: 23] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
6 Jönsson F, Kreppel F. Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5. Virus Genes 2017;53:692-9. [PMID: 28755290 DOI: 10.1007/s11262-017-1498-z] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
7 Reale A, Messa L, Vitiello A, Loregian A, Palù G. 4th European Seminars in Virology on Oncogenic and Oncolytic Viruses, in Bertinoro (Bologna), Italy. J Cell Physiol 2017;232:2641-8. [PMID: 27859242 DOI: 10.1002/jcp.25692] [Reference Citation Analysis]
8 Chira S, Jackson CS, Oprea I, Ozturk F, Pepper MS, Diaconu I, Braicu C, Raduly LZ, Calin GA, Berindan-Neagoe I. Progresses towards safe and efficient gene therapy vectors. Oncotarget 2015;6:30675-703. [PMID: 26362400 DOI: 10.18632/oncotarget.5169] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 19.3] [Reference Citation Analysis]
9 Riedl SJ, Pasquale EB. Targeting the Eph System with Peptides and Peptide Conjugates. Curr Drug Targets 2015;16:1031-47. [PMID: 26212263 DOI: 10.2174/1389450116666150727115934] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
10 Appaiahgari MB, Vrati S. Adenoviruses as gene/vaccine delivery vectors: promises and pitfalls. Expert Opinion on Biological Therapy 2015;15:337-51. [DOI: 10.1517/14712598.2015.993374] [Cited by in Crossref: 69] [Cited by in F6Publishing: 53] [Article Influence: 8.6] [Reference Citation Analysis]